Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

被引：3
|
作者：
Hill, A [1 ]
机构：
[1] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
AIDS | 2005年 / 19卷 / 17期
关键词：
D O I：
10.1097/01.aids.0000194137.73876.d5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：2
相关论文
共 50 条
  • [41] Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients
    Stanley, Takara L.
    Joy, Tisha
    Hadigan, Colleen M.
    Liebau, James G.
    Makimura, Hideo
    Chen, Cindy Y.
    Thomas, Bijoy J.
    Weise, Steven B.
    Robbins, Gregory K.
    Grinspoon, Steven K.
    AIDS, 2009, 23 (11) : 1349 - 1357
  • [42] Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation
    Boffito, Marta
    Else, Loura
    Back, David
    Taylor, Jessica
    Khoo, Saye
    Sousa, Marta
    Pozniak, Anton
    Gazzard, Brian
    Moyle, Graeme
    ANTIVIRAL THERAPY, 2008, 13 (07) : 901 - 907
  • [43] Influence of Baseline Protease Inhibitor Resistance on the Efficacy of Darunavir/Ritonavir or Lopinavir/Ritonavir in the TITAN Trial
    De Meyer, Sandra
    Hill, Andrew
    Picchio, Gaston
    DeMasi, Ralph
    De Paepe, Els
    de Bethune, Marie-Pierre
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 49 (05) : 563 - 564
  • [44] The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration
    Bierman, Wouter F. W.
    van Vonderen, Marit G. A.
    Veldkamp, Agnes I.
    Burger, David M.
    Danner, Sven A.
    Reiss, Peter
    van Agtmael, Michiel A.
    ANTIVIRAL THERAPY, 2011, 16 (05) : 647 - 655
  • [45] Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
    McCance-Katz, Elinore F.
    Moody, David E.
    Morse, Gene D.
    Ma, Qing
    DiFrancesco, Robin
    Friedland, Gerald
    Pade, Patricia
    Rainey, Petrie M.
    DRUG AND ALCOHOL DEPENDENCE, 2007, 91 (2-3) : 269 - 278
  • [46] Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure
    Di Giambenedetto, S.
    De Luca, A.
    Villani, P.
    Bacarelli, A.
    Ragazzoni, E.
    Regazzi, M.
    Cauda, R.
    Navarra, P.
    HIV MEDICINE, 2008, 9 (04) : 239 - 245
  • [47] THE FINANCIAL INCENTIVE TO MARKET SECONDARY PATENT OF RITONAVIR AND LOPINAVIR/RITONAVIR
    Vernaz, N.
    Cohen, G.
    Combescure, C.
    Ledergerber, B.
    Calmy, A.
    SEXUALLY TRANSMITTED INFECTIONS, 2017, 93 : A256 - A256
  • [48] Small dense LDL in HIV-infected patients treated with lopinavir/ritonavir or atazanavir
    Richter, W. O.
    Berger, F.
    Mauss, S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 401 - 401
  • [49] Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks
    Pulido, F.
    Estrada, V.
    Baril, J. G.
    Logue, K.
    Schewe, K.
    Plettenberg, A.
    Duiculescu, D.
    Yau, L.
    Vavro, C.
    Lim, M. L.
    Pharo, C.
    HIV CLINICAL TRIALS, 2009, 10 (02): : 76 - 87
  • [50] Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: Reversion after switching (Stavudine to tenofovir and Lopinavir/Ritonavir to Atazanavir/Ritonavir)
    Domingos, Hamilton
    da Cunha, Rivaldo Venancio
    Paniago, Anamaria Mello Miranda
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (02): : 290 - 292
12345